Press coverage about Verastem (NASDAQ:VSTM) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Verastem earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 83 out of 100, meaning that recent press coverage is very likely to have an effect on the stock’s share price in the next few days.

These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:

Verastem (VSTM) traded down 2.8345% during mid-day trading on Monday, hitting $3.6097. 442,833 shares of the stock were exchanged. The company has a 50-day moving average price of $2.25 and a 200-day moving average price of $1.66. Verastem has a one year low of $1.05 and a one year high of $4.67. The company’s market cap is $133.53 million.

Verastem (NASDAQ:VSTM) last announced its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.35) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.35). Analysts forecast that Verastem will post ($1.31) earnings per share for the current fiscal year.

A number of brokerages have recently weighed in on VSTM. Zacks Investment Research raised shares of Verastem from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a report on Thursday. Jefferies Group LLC reissued a “hold” rating and set a $1.50 price objective on shares of Verastem in a report on Wednesday, June 28th. Cann reissued a “buy” rating and set a $6.00 price objective on shares of Verastem in a report on Monday, June 26th. Cantor Fitzgerald reissued a “hold” rating and set a $2.00 price objective on shares of Verastem in a report on Thursday, June 8th. Finally, Oppenheimer Holdings, Inc. set a $6.00 price objective on shares of Verastem and gave the company a “buy” rating in a report on Sunday, June 4th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $4.54.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Very Likely to Affect Verastem (VSTM) Share Price” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.watchlistnews.com/somewhat-positive-news-coverage-very-likely-to-affect-verastem-vstm-share-price/1445459.html.

In related news, Director Timothy J. Barberich acquired 30,000 shares of Verastem stock in a transaction that occurred on Monday, May 15th. The stock was purchased at an average price of $2.45 per share, for a total transaction of $73,500.00. Following the completion of the purchase, the director now directly owns 69,462 shares of the company’s stock, valued at $170,181.90. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

About Verastem

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

Insider Buying and Selling by Quarter for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.